OrbitonOpen research workspace →
Bioventus Inc. Class A Common Stock logo

Bioventus Inc. Class A Common Stock

NASDAQ:BVSLive AI agent

Bioventus is a global leader in orthobiologic solutions, dedicated to helping patients regain mobility and improve their quality of life.

Investor website: https://bioventus.com/

About

Bioventus is a global leader in orthobiologic solutions, dedicated to helping patients regain mobility and improve their quality of life. The company focuses on developing innovative products that enhance healing and recovery, particularly in the areas of pain treatment and restorative therapies. Bioventus is committed to advancing the science of healing through research and development, and it emphasizes a patient-centered approach in its operations. The leadership team comprises experienced professionals from various fields, ensuring a robust strategy for growth and sustainability.

Verified company data

Cash position
$29,457
Shares outstanding
60601858
Fully diluted shares
68,837,797
Projects
["MEMPHIS, TN – November 18, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has signed a lease agreement to double its current operations and manufacturing space and relocate from its current facility in suburban Memphis. Bioventus expects to move its 116 employees into the new space in early Q3 of 2022 and add another 40 jobs in the next five years. “As we revised our operational plan in alignment with the Company’s strategy, we determined that the expansion of our Memphis location would be required to manage our organic growth, vertical integration of key manufacturing capabilities and our additional growth through acquisitions,” said Miguel Beltran-Delgado, Senior Vice President of Operations, Bioventus. “We are very pleased we could identify and secure this new location, which is right across the way from our current site, minimizing the disruption to our employees and customers, while meeting our near and long term operations and manufacturing needs.” The current location began operations in 2012 and the new facility will be located at 7101 Goodlett Farms Parkway in Cordova, TN. It includes approximately 90,000 total square feet of space and will feature approximately 55,000 square feet dedicated to light manufacturing and operations. The remaining 35,000 square feet will be developed for offices, conference rooms and shared workspaces. Cushman & Wakefield│Commercial Advisors represented Bioventus on the lease for this new facility."]
Leadership
Robert Claypoole (Chief Executive Officer), Mark Singleton (Senior Vice President and Chief Financial Officer), Katrina Church (Chief Compliance Officer), Anthony D’Adamio (Senior Vice President and General Counsel), Helen Leupold (Senior Vice President, Chief Human Resources Officer, responsible for leading all aspects of human resources and communications with over two decades of HR leadership experience.), Mike Crowe (Senior Vice President, Operations), Anthony Doyle (SVP, General Manager, Pain Treatment & Restorative Therapies), Megan Rosengarten (SVP, General Manager, Peripheral Nerve Stimulation), Dave Venner (SVP, General Manager, Surgical), Jeff Ciardi (Vice President of Strategic Accounts and Market Access), Jane Fitzpatrick (Vice President of Medical Affairs), Kellie Stefaniak (Vice President of Global Regulatory and Quality), Sharath Bhat (Vice President/General Manager, EMEA APAC), Peter Shaw (Vice President of Medical Affairs and Chief Medical Officer, with extensive experience in medical affairs and a background in clinical practice.), David Rennie (General Manager, International, responsible for leading the company’s international business with over 25 years in the medical device industry.)

Verified data last updated:

Recent filings